Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Go Back

Share this story

Comments


Related articles


yanair airplane at Bergamo airport in Italy

Perspectives

Campaigners slam Ryanair for Parkinson’s ‘drunk’ flight ban

No-fly zone for holidaymaker with Parkinson’s

READ MORE
Women and Parkinson's menopause

Women and Parkinson's

“We need to be having more conversations about menopause”

One woman’s story about the approach of menopause

READ MORE
WPC 2016

Interviews

Meet Andy Butler, the man behind the Parkinson’s People Facebook group

One of Facebook’s largest independent Parkinson’s groups

READ MORE